Evofem Biosciences, Inc. (EVFM)
| Market Cap | 13.82M |
| Revenue (ttm) | 13.56M |
| Net Income (ttm) | 46.76M |
| Shares Out | 215.96M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,316,023 |
| Open | 0.0695 |
| Previous Close | 0.0690 |
| Day's Range | 0.0590 - 0.0750 |
| 52-Week Range | 0.0530 - 10.0000 |
| Beta | -1.21 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Aug 29, 2023 |
About EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. [Read more]
Financial Performance
In 2022, EVFM's revenue was $16.84 million, an increase of 104.23% compared to the previous year's $8.24 million. Losses were -$76.70 million, -62.62% less than in 2021.
Financial StatementsNews
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Bioscienc...
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt
MILWAUKEE , Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt. Click here...
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 8...
Evofem to Participate in the Virtual Investor Ask the CEO Conference
-- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET -- SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the...
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
-- Padagis Determined They Will Not Challenge the Phexxi Patents -- -- Evofem Has Phexxi Patent Protection Through 2033 -- SAN DIEGO , Sept. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQ...
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
-- Investor withdraws March 2023 Notice of Default -- -- Notes are no longer convertible to shares of common stock, removing potential dilution from the previously-reserved over 240 million shares of...
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
SAN DIEGO , Aug. 22, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced it has signed a confidential non-binding letter of intent (LOI) relating to a p...
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 6...
Evofem to Participate in the Virtual Investor Summer Spotlight Series
-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12 th at 4:00 p.m. ET -- SAN DIEGO , July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the...
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
-- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to "EVFMD" for 20 business days, then revert to "EVFM" -- SAN DIEGO , May 17, 2023 /PRNewswire/ -- E...
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs.
Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
SAN DIEGO , April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zha...
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid and pot...
Evofem Biosciences Announces Cost Reduction Measures
– Company cuts management pay and lowers headcount to decrease operating costs – – Reductions align with corporate goal to reach cash flow break even by year-end 2023 – SAN DIEGO , March 21, 2023 /PRN...
Evofem Biosciences Appoints Interim Chief Financial Officer
SAN DIEGO , March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces J...
Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering
-- Phexxi is the first and only hormone-free contraceptive offered by reproductive telehealth leader SimpleHealth to its patients -- SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. ...
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S...
Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value
SAN DIEGO , Feb. 23, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM), announced today that its Board of Directors has unanimously approved a comprehensive strategic process to explore and ...
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)
-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio -- SAN DIEGO , Jan. 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that femal...
Costco Adds Phexxi® to Member Prescription Program
SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi ® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Pres...
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women
-- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states -- -- Largest commercial insurer in Michigan and a marquis university plan in Pennsylvania move Phexxi to Preferre...
OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
SAN DIEGO , Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form ...
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women
SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chl...
Evofem Biosciences Announces Approval of Phexxi in Nigeria
-- First Regulatory Approval Outside the U.S. -- SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has be...
Evofem Biosciences Announces Uplisting to OTCQB
SAN DIEGO , Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink O...